41 results
DFAN14A
EXEL
Exelixis Inc
11 May 23
Additional proxy materials by non-management
12:27pm
, February 23, 2022 “ The science and innovation is subpar at best with Exelixis relying heavily on its one hit wonder drug.” 1 – Anonymous Former Employee … 64 Nominee Current & Past Affiliations Experience Tom Heyman Former President Johnson & Johnson Innovation + Interim, part - time CEO of Interlaken
DEFA14A
EX-1
EXEL
Exelixis Inc
1 May 23
Additional proxy soliciting materials
8:55pm
for patients. Exelixis’ robust innovation and Advancing our wholly-owned assets: zanzalintinib, a next-generation discovery pipeline is fueling tyrosine kinase … without the need for dilutive financings. When we effectively invest in innovation, the pipeline and our platforms, we maximize our opportunities
DEFA14A
EXEL
Exelixis Inc
1 May 23
Additional proxy soliciting materials
5:12pm
to advance meaningful therapies for patients.
Exelixis’ robust innovation and discovery pipeline is fueling our strong momentum as we move through 2023 … revenues to invest in growing our business without the need for dilutive financings. When we effectively invest in innovation, the pipeline and our
DEFC14A
l3756h2s
1 May 23
Proxy in contested solicitation
4:58pm
PREC14A
6l9j byo7pbo
17 Apr 23
Preliminary proxy with contested solicitation
4:57pm
DEFA14A
EX-99.1
1wq a1361m08u4is
13 Apr 23
Additional proxy soliciting materials
4:27pm
8-K
EX-99.1
6t556 0ky
13 Apr 23
Departure of Directors or Certain Officers
4:26pm
8-K
EX-99.1
uagm zhbgn
10 Jan 22
Results of Operations and Financial Condition
4:30pm